Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's

Related Keywords

United States ,Proctitis Proctosigmoiditis ,Leo Ehrlich ,Innovation Pharmaceuticals Inc ,Company Brilacidin Phase ,Drug Administration ,Antiviral Program For Pandemics ,Company Compassionate ,Exchange Commission ,Brilacidin Antiviral Program ,National Early Warning Score ,Innovation Pharmaceuticals ,Brilacidin Phase ,Chief Executive Officer ,Sustained Recovery Through Day ,Intent To Treat Population ,Patient Subgroup ,Highest Quartile Baseline Values ,Per Protocol Population ,C Reactive Protein ,Load Biomarker ,Compassionate Use ,Observed Treatment ,Brilacidin Oral Mucositis ,Ulcerative Colitis ,Looking Statements ,Private Securities Litigation Reform Act ,Innovation ,Pharmaceuticals ,Reports ,Dditional ,Findings ,Ased ,Review ,Brilacidin ,Hase ,Covid ,Trial ,Results ,Compassionate ,Cases ,